Jasper Therapeutics, Inc. 8-K

What Happened

• Jasper Therapeutics, Inc. (JSPR) announced and filed a Current Report on Form 8‑K on May 14, 2026 reporting its financial results for the quarter ended March 31, 2026 and providing a corporate update. The company issued a press release with those results, which is furnished as Exhibit 99.1 to the 8‑K.

Key Details

• Filing date: May 14, 2026 (Form 8‑K, Item 2.02: Results of Operations and Financial Condition).
• Reporting period: Quarter ended March 31, 2026 (Q1 2026).
• Press release: Furnished as Exhibit 99.1 to the 8‑K.
• Legal note: The press release is furnished under General Instructions B.2 of Form 8‑K and therefore is not deemed “filed” for purposes of Section 18 of the Exchange Act and is not automatically incorporated by reference into other filings.

Why It Matters

• This 8‑K signals that Jasper has released its quarterly financial results and a corporate update; retail investors should read the Exhibit 99.1 press release to see the specific revenue, earnings, cash position, guidance or other metrics.
• Because the release is furnished (not “filed”), the company is providing timely information but limited the legal liabilities associated with a filed exhibit; any material changes or forward‑looking disclosures may appear in future filings.